Moderna’s first-quarter revenue topped expectations, powered largely by strong international COVID-19 vaccine sales. While the company expects lower-than-anticipated revenue in Q2, it is betting on longer-term growth, targeting a major slice of Europe’s respiratory vaccine market. Its mCombriax launch is planned for 2027, shifting investor focus beyond COVID.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
